306 related articles for article (PubMed ID: 32158253)
1. Alkaptonuria: Current Perspectives.
Zatkova A; Ranganath L; Kadasi L
Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
[TBL] [Abstract][Full Text] [Related]
2. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
3. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
[TBL] [Abstract][Full Text] [Related]
4. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
[TBL] [Abstract][Full Text] [Related]
5. Development of an Effective Therapy for Alkaptonuria - Lessons for Osteoarthritis.
Gallagher JA; Dillon JP; Ranganath LR
Rheumatol Immunol Res; 2021 Jun; 2(2):79-85. PubMed ID: 36465977
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Phenotype Differences in Siblings with Alkaptonuria.
Zatkova A; Olsson B; Ranganath LR; Imrich R
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295892
[TBL] [Abstract][Full Text] [Related]
7. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
8. Alkaptonuria: a very rare metabolic disorder.
Aquaron R
Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
[TBL] [Abstract][Full Text] [Related]
9. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
[TBL] [Abstract][Full Text] [Related]
10. Natural history of alkaptonuria revisited: analyses based on scoring systems.
Ranganath LR; Cox TF
J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
[TBL] [Abstract][Full Text] [Related]
11. An update on molecular genetics of Alkaptonuria (AKU).
Zatkova A
J Inherit Metab Dis; 2011 Dec; 34(6):1127-36. PubMed ID: 21720873
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
Braconi D; Millucci L; Bernardini G; Santucci A
Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
[TBL] [Abstract][Full Text] [Related]
13. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
Ranganath LR; Heseltine T; Khedr M; Fisher MF
Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
[TBL] [Abstract][Full Text] [Related]
16. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria.
Taylor AM; Vercruysse KP
JIMD Rep; 2017; 35():79-85. PubMed ID: 27943071
[TBL] [Abstract][Full Text] [Related]
18. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
19. Untargeted NMR Metabolomics Reveals Alternative Biomarkers and Pathways in Alkaptonuria.
Grasso D; Geminiani M; Galderisi S; Iacomelli G; Peruzzi L; Marzocchi B; Santucci A; Bernini A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555443
[TBL] [Abstract][Full Text] [Related]
20. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]